Abstract: A separator for a lithium-sulfur battery and a lithium-sulfur battery including the same is provided. More particularly, a separator for a lithium-sulfur battery including a porous substrate; and a coating layer present on at least one surface of the porous substrate, wherein the coating layer includes a polymer and a graphitic carbon-based compound, wherein the polymer includes a main chain with a functional group having a non-covalent electron pair present in the main chain and a side chain with an aromatic hydrocarbon group present in the side chain.

Abstract: A ceria-carbon-sulfur (CeO2—C—S) composite including a ceria-carbon (CeO2—C) composite in which cylindrical carbon materials having ceria (CeO2) particles bonded to surfaces thereof are entangled and interconnected to each other in three dimensions; and sulfur introduced into at least a portion of an outer surface and an inside of the ceria-carbon composite, a method for preparing the same, and positive electrode for a lithium-sulfur battery and a lithium-sulfur battery including the same.

Abstract: A canister for a semiconductor manufacturing device according to an embodiment of the present disclosure is provided with a sintered filter at the end of a dip tube into which a carrier gas is to be injected, and further provided with a porous container having excellent heat transfer rate inside a container, so that the precursor material filled inside the canister can be smoothly supplied to the thin film deposition device at a rear stage.

Abstract: The present disclosure relates to a use of H2AFZ as a hepatocellular carcinoma (HCC) biomarker and more particularly, to a marker for diagnosing hepatocellular carcinoma consisting of a H2AFZ gene or an expression protein H2A.Z.1 thereof, a composition for diagnosing or estimating prognosis of HCC, a method for diagnosing or estimating prognosis of HCC, a method of detecting a biomarker for diagnosing or estimating prognosis of HCC, a screening method of an HCC therapeutic agent, and a pharmaceutical composition for preventing or treating HCC.

Abstract: The present disclosure relates to a use of H2AFZ as a hepatocellular carcinoma (HCC) biomarker and more particularly, to a marker for diagnosing hepatocellular carcinoma consisting of a H2AFZ gene or an expression protein H2A.Z.1 thereof, a composition for diagnosing or estimating prognosis of HCC, a method for diagnosing or estimating prognosis of HCC, a method of detecting a biomarker for diagnosing or estimating prognosis of HCC, a screening method of an HCC therapeutic agent, and a pharmaceutical composition for preventing or treating HCC. As it is verified that the expression level of the H2AFZ gene according to the present disclosure is increased in an HCC tissue or HCC cells compared to a non-HCC tissue or non-HCC cells, in the case of using the H2AFZ gene as the marker for diagnosing the HCC, the HCC can be rapidly and accurately diagnosed and predicted in early stages and the H2AFZ gene can be used as a target for developing a therapeutic agent for preventing or treating the HCC.

Abstract: The present invention relates to a non-invasive blood glucose sensor, comprising: a substrate, a first metal layer, a second metal layer, and a blood glucose sensing unit, wherein the first metal layer is formed on the one surface of the substrate and has a microstrip antenna in the internal thereof, the second metal layer is formed on the other surface of the substrate, and the blood glucose sensing unit is electrically connected to the first metal layer and the second metal layer. In the present invention, the non-invasive blood glucose sensor can be used to measure a numerical value of the blood glucose in a human body by way of disposing the non-invasive blood glucose sensor near the human body, without using any body-invading ways, for example, the acupuncture treatment; therefore the inconveniences and incorrect measurements resulting from the body-invading ways can be avoided.

Abstract: Disclosed herein is a colorless and transparent antibiotic material including silver and a method of preparing the same. Specifically, the current invention pertains to a method of preparing a colorless and transparent antibiotic material including silver (Ag), which includes a) reacting a salt including a silver ion (Ag+) with a salt including a sulfate anion, to prepare a silver (Ag)-sulfate complex; and b) diluting the silver (Ag)-sulfate complex prepared in a) with water, and to an antibiotic material prepared using the method. Further, the current invention pertains to an antibiotic material including silver, which is harmless to the human body and exhibits disinfecting and antibiotic activities, and as well, is colorless and transparent and does not easily form colored oxides, unlike conventional silver-based antibiotic materials, and to a method of preparing such an antibiotic material.

Abstract: The invention relates generally to the changes in gene expression in human tissues from cancer patients. The invention relates specifically to human gene families which are differentially expressed in cancer tissues of breast, colon, esophagus, kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, and/or stomach compared to corresponding normal tissues.